Objective To evaluate the efficacy of anti-oxidative treatment in cats with pancreaticobiliary maljunction. Methods Thirteen healthy cats as control group were made a model that resembling the common channel of pancreaticobiliary maljunction as in humans，and were divided randomly into two groups：7 cats in untreated group were not treated，6 cats in anti-oxidative group were treated with melatonin，vitamin C， and vitamin E. Six months later， the gallbladders of these animals were removed and histopathological changes were evaluated by pathological and electron microscopic examination. The level of MDA，amylase concentration in the gallbladder bile，and percentage of proliferating cell nuclear antigen （PNCA） positive cells were also test. Results All cats had survived for 6 months after operation. The wall of gallbladder and the bile became thicker in untreated group than that in normal control group， and there were no significant differences between untreated group and anti-oxidative group. The gallbladder epithelium became villous in appearance in untreated group，although the epithelium of that in normal control group was flat with few folds. The epithelial cells of gallbladder arranged tightly in normal control group， while a significant change such as endoplasmic reticulum expanding， intercellular space broadening， and cellular nucleus deforming were observed in untreated group. The things in anti-oxidative group were better than untreated group. The amylase concentration in the gallbladder bile was （203.02±65.04）U in normal control group，（9 368.09±2 204.42） U in untreated group， and（8 746.25±2 077.95） U in anti-oxidative group， respectively. The amylase concentration in untreated group and anti-oxidative group were higher than that in normal control group （P=0.003），and there was no significant difference between the untreated group and anti-oxidative group （P=0.642）. The percentage of PNCA positive cells was （7.29±2.70）% in normal control group，（54.71±10.90）% in untreated group, and （48.17±13.06）% in anti-oxidative group， respectively （F=48.11，P=0.001），and the percentage of PNCA positive cells in untreated group was higher than that in anti-oxidative group （P=0.001）. The level of MDA was （1.095±0.653） nmol/mg prot in normal control group，（2.745±1.533） nmol/mg prot in untreated group, and （1.302±0.771） nmol/mg prot in anti-oxidative group， respectively （F=5.17，P=0.017）, and the level of MDA in untreated group was higher than that in anti-oxidative group （P=0.017）. Conclusion The anti-oxidative treatment is effective to pancreaticobiliary maljunction.
ObjectiveTo investigate the clinical significance of applying digitalis preparations after pneumonec-tomy. MethodsWe retrospectively analyzed the clinical data of 78 patients who underwent pneumonectomy in the Tangdu Hospital of The Fourth Military Medical University from August 2010 to August 2013. The patients were divided into a control group (39 patients with 27 males and 12 females at a mean age of 56.8±14.8 years) and a trial group (39 patients with 24 males and 15 females at a mean age of 57.4±10.1 years). After pneumonectomy, the trial group received low dose of digitalis treatment. On 3, 5, and 7 days, the arterial partial pressure of oxygen (PaO2), systolic pulmonary artery pressure (SPAP), mean arterial pressure (MAP), diastolic pulmonary artery pressure (DPAP), and the rate of complications were examined. ResultsAfter treatment with the low dose of digitalis, the SPAP, MAP, DPAP of the trial group were statistically lower than those of the control group (P < 0.05). Incidence of arrhythmia in the trial group was statistically lower than that of the control group (P < 0.05). There was no statistical difference between the two groups in the PaO2, the incidence of pulmonary infection, and circulation disorder (P > 0.05). ConclusionLow dose of digitalis preparations can improve cardiac function after pneumonectomy.
ObjectivesTo systematically review the clinical response rate of CD19 chimeric antigen receptor modified-T cells (CD19CART) in the treatment of B cell hematological malignancies.MethodsPubMed, EMbase, CNKI, WanFang Data and VIP databases were searched to collect cohort studies about CD19CART in the treatment of B cell hematological malignancies from 2000 to 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, a single rate meta-analysis was performed by R software and SPSS 16.0 software.ResultsA total of 13 prospective cohort studies were included. The results of single group rate meta-analysis showed that the overall pooled response rate of CD19 CART was 68% (95%CI 0.51 to 0.82). The 6 months and 1-year PFS after CD19 CART infused by Kaplan-Meier were 46% (95%CI 0.35 to 0.56) and 24% (95%CI 0.16 to 0.34), respectively. The median duration was 180 days (95%CI 138 to 222). The COX regression model showed lymphodepletion to be the only influence factor of PFS.ConclusionsCD19 CART has a good clinical response rate in the treatment of B cell hematological malignancies. Lymphodepletion is the only important impact on the response rate and PFS. Due to limited quality and quantity of included studies, more high quality studies are required to verify the above conclusions.
ObjectiveTo explore whether surgery combined with adjuvant chemotherapy can bring survival benefits to patients with cervical and upper thoracic esophageal squamous cell carcinoma (ESCC).MethodsThe clinical data of patients with cervical and upper thoracic ESCC who underwent R0 resection and neck anastomosis in our department from 2006 to 2010 were retrospectively analyzed. Patients received neoadjuvant therapy or adjuvant radiotherapy were excluded. The adjuvant chemotherapy group was given a combination of taxanes and platinum based chemotherapy after surgery; the surgery alone group did not receive adjuvant chemotherapy. The Kaplan-Meier method was used to analyze the survival difference between the adjuvant chemotherapy group and the surgery alone group. ResultsA total of 181 patients were enrolled, including 141 (77.9%) males and 40 (22.1%) females, with an average age of 61.0±8.2 years (80 patients aged≤61 years, 101 patients aged>61 years). There were 70 (38.7%) patients of cervical ESCC, and 111 (61.3%) patients of upper thoracic ESCC. Eighty-seven (48.1%) patients underwent postoperative adjuvant chemotherapy, and 94 (51.9%) patients underwent surgery alone, and the basic clinical characteristics were well balanced between the two groups (P>0.05). The median survival time of patients in the adjuvant chemotherapy group and the surgery alone group was 31.93 months and 26.07 months, and the 5-year survival rate was 35.0% and 32.0%, respectively (P=0.227). There was no statistical difference in median survival time between the cervical ESCC and upper thoracic ESCC group (31.83 months vs. 29.76 months, P=0.763). For cervical ESCC patients, the median survival time was 45.07 months in the adjuvant chemotherapy group and 14.70 months in the surgery alone group (P=0.074). Further analysis showed that the median survival time of lymph node negative group was 32.53 months, and the lymph node positive group was 24.57 months (P=0.356). The median survival time was 30.43 months in the lymph-node positive group with adjuvant chemotherapy and 17.77 months in the lymph-node positive group with surgery alone. The survival curve showed a trend of difference, but the difference was not statistically significant (P=0.557).ConclusionThere is no statistical difference in the long-term survival of cervical and upper thoracic ESCC patients after R0 resection. Postoperative adjuvant chemotherapy may have survival benefits for patients with cervical ESCC and upper ESCC with postoperative positive lymph nodes, but the differences are not statistically significant in this setting.